LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study
10.1016/j.annonc.2022.08.016 · doi-reference
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
10.1038/s41591-020-0805-8 · doi-reference
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
10.1038/s41591-022-01851-x · doi-reference
Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials
10.1016/j.annonc.2023.01.004 · doi-reference
Pembrolizumab for Early Triple-Negative Breast Cancer
10.1056/nejmoa1910549 · doi-reference
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
10.1056/nejmoa2202170 · doi-reference
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
10.1056/nejmoa2032125 · doi-reference
804P Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial
10.1016/j.annonc.2022.07.930 · doi-reference
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
10.1056/nejmoa1802357 · doi-reference
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
10.1158/1078-0432.ccr-22-3145 · doi-reference
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
10.1016/s0140-6736(22)01654-3 · doi-reference
Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K)
10.25251/skin.7.supp.163 · doi-reference
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
10.1056/nejmoa1709030 · doi-reference
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
10.1016/s0140-6736(22)00562-1 · doi-reference
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
10.1056/nejmoa2034442 · doi-reference
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
10.1056/nejmoa2106391 · doi-reference
IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC)
10.1200/jco.2021.39.15_suppl.8500 · doi-reference
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
10.1016/s1470-2045(22)00518-6 · doi-reference
Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients
10.1126/science.abf3363 · doi-reference
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
10.1126/science.abb5920 · doi-reference
Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
10.1056/nejmoa2211437 · doi-reference
